Abubacar, Pikaw L.

HRN: 14-63-73  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
07/28/2022
CEFTAZIDIME 1GM (VIAL)
07/28/2022
08/03/2022
IV
1g
Q8
DM Foot
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Skin & Soft Tissue    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: